197 related articles for article (PubMed ID: 25424788)
1. Dendritic cell immunotherapy in uterine cancer.
Coosemans A; Tuyaerts S; Vanderstraeten A; Vergote I; Amant F; Van Gool SW
Hum Vaccin Immunother; 2014; 10(7):1822-7. PubMed ID: 25424788
[TBL] [Abstract][Full Text] [Related]
2. Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman ZN; Vergote I; Amant F; VAN Gool SW
Anticancer Res; 2013 Dec; 33(12):5495-500. PubMed ID: 24324087
[TBL] [Abstract][Full Text] [Related]
3. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Coosemans A; Vergote I; Van Gool SW
Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
[TBL] [Abstract][Full Text] [Related]
4. Understanding dendritic cell immunotherapy in ovarian cancer.
Drakes ML; Stiff PJ
Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer.
Vanderstraeten A; Everaert T; Van Bree R; Verbist G; Luyten C; Amant F; Tuyaerts S
J Immunother; 2015; 38(6):239-49. PubMed ID: 26049547
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells and pluripotency: unlikely allies in the pursuit of immunotherapy.
Fairchild PJ; Leishman A; Sachamitr P; Telfer C; Hackett S; Davies TJ
Regen Med; 2015; 10(3):275-86. PubMed ID: 25933237
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol.
Baert T; Garg AD; Vindevogel E; VAN Hoylandt A; Verbist G; Agostinis P; Vergote I; Coosemans AN
Anticancer Res; 2016 Nov; 36(11):5793-5801. PubMed ID: 27793901
[TBL] [Abstract][Full Text] [Related]
10. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based immunoregulatory strategies.
Matsue H; Kusuhara M; Matsue K; Takashima A
Int Arch Allergy Immunol; 2002 Apr; 127(4):251-8. PubMed ID: 12021543
[TBL] [Abstract][Full Text] [Related]
12. [The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer - 229 clinical cases].
Nakamura K; Hanazawa S; Takeda T; Sumiyoshi R; Kobayashi S; Takeda H; Takeda T
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1295-7. PubMed ID: 25335722
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell immunobiology and potential roles in immunotherapy.
Fadilah SA; Cheong SK
Malays J Pathol; 2007 Jun; 29(1):1-18. PubMed ID: 19108040
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell immunotherapy: mapping the way.
Figdor CG; de Vries IJ; Lesterhuis WJ; Melief CJ
Nat Med; 2004 May; 10(5):475-80. PubMed ID: 15122249
[TBL] [Abstract][Full Text] [Related]
15. Nonviral transfection of human umbilical cord blood dendritic cells is feasible, but the yield of dendritic cells with transgene expression limits the application of this method in cancer immunotherapy.
Markowicz S; Niedzielska J; Kruszewski M; Ołdak T; Gajkowska A; Machaj EK; Skurzak H; Pojda Z
Acta Biochim Pol; 2006; 53(1):203-12. PubMed ID: 16404477
[TBL] [Abstract][Full Text] [Related]
16. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
Rossowska J; Pajtasz-Piasecka E
Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell immunotherapy in soft tissue sarcoma.
Indelicato DJ; Finkelstein SE
Immunotherapy; 2012 Oct; 4(10):1023-9. PubMed ID: 23148754
[TBL] [Abstract][Full Text] [Related]
19. [Dendritic cells for cancer immunotherapy].
Kakimi K; Kondo A; Matsushita H
Nihon Rinsho; 2012 Dec; 70(12):2130-5. PubMed ID: 23259385
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.
Van Nuffel AM; Corthals J; Neyns B; Heirman C; Thielemans K; Bonehill A
Methods Mol Biol; 2010; 629():405-52. PubMed ID: 20387165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
